6-Acetylmethylenepenicillanic acid | 83151-26-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6-Acetylmethylenepenicillanic acid
• 英文别名: (2S,5R,6E)-3,3-dimethyl-7-oxo-6-(2-oxopropylidene)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 83151-26-2
• 化学式: C₁₁H₁₃NO₄S
• 分子量: 255.29
• InChiKey: IKGZFJCMJFERPR-CNEXKXPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA
  申请人：Nishino Taito

  公开号：US20130253204A1

  公开（公告）日：2013-09-26

  Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R 1 is C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with R 17 , C 1 -C 6 haloalkyl, phenyl, phenyl substituted with a R 11 's or the like, R 2 is a hydrogen atom, C 1 -C 6 alkyl, phenyl or phenyl optionally substituted with e R 21 's or the like, R 3 is a hydrogen atom or the like, X is a single bond or —(CR 6 , R 7 ) n —, each of R 4 and R 5 is independently C 1 -C 6 alkyl or the like, R 6 and R 7 are hydrogen atoms or C 1 -C 6 alkyl, R 8 is phenyl, phenyl optionally substituted with k R 81 's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

  提供了用于骨髓瘤的新型治疗药物。一种用于多发性骨髓瘤的治疗剂，包含由式（1）表示的吡唑烷化合物：其中R1是C1-C6烷基，C1-C6烷基取代为R17，C1-C6卤代烷基，苯基，苯基取代为R11或类似物，R2是氢原子，C1-C6烷基，苯基或可选地取代为e个R21或类似物，R3是氢原子或类似物，X是单键或—（CR6，R7)n—，R4和R5分别独立地是C1-C6烷基或类似物，R6和R7是氢原子或C1-C6烷基，R8是苯基，苯基可选地取代为k个R81或类似物，所述化合物的互变异构体或其药用上可接受的盐或溶剂，作为活性成分。
• Bismuth compounds for the treatment and prevention of mucositis
  申请人：GelTex Pharmaceuticals, Inc.

  公开号：US20020081340A1

  公开（公告）日：2002-06-27

  The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.

  本发明涉及到一种意外发现：含铋化合物在哺乳动物的口腔粘膜炎症治疗中具有有效性。因此，本发明在一个方面涉及到一种治疗口腔粘膜炎症的方法，包括给予有效量的药用可接受的含铋化合物，例如铋盐或铋配合物。在一个优选实施例中，铋化合物是有机或无机盐，例如铋亚水杨酸盐、铋亚没食子酸盐、铋铝酸盐、铋柠檬酸盐、铋亚柠檬酸盐、铋碳酸盐、铋亚碳酸盐、三钾柠檬酸铋酸盐、铋硝酸盐、铋亚硝酸盐、铋酒石酸盐及其混合物，优选地，铋亚水杨酸盐和铋亚没食子酸盐。
• PYRAZOLE COMPOUND HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP2647629A1

  公开（公告）日：2013-10-09

  Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R1 is C1-C6 alkyl, C1-C6 alkyl substituted with R17, C1-C6 haloalkyl, phenyl, phenyl substituted with a R11's or the like, R2 is a hydrogen atom, C1-C6 alkyl, phenyl or phenyl optionally substituted with e R21's or the like, R3 is a hydrogen atom or the like, X is a single bond or -(CR6 R7)n -, each of R4 and R5 is independently C1-C6 alkyl or the like, R6 and R7 are hydrogen atoms or C1-C6 alkyl, R8 is phenyl, phenyl optionally substituted with k R81's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

  提供了治疗骨髓瘤的新型治疗剂。 一种治疗多发性骨髓瘤的药物含有由式（1）代表的吡唑化合物： 其中 R1 是 C1-C6 烷基、被 R17 取代的 C1-C6 烷基、C1-C6 卤代烷基、苯基、被一个 R11 取代的苯基或类似物，R2 是氢原子、C1-C6 烷基、苯基或任选被 e 个 R21 取代的苯基或类似物，R3 是氢原子或类似物，X 是单键或-(CR6 R7)n -、R4和R5各自独立地为C1-C6烷基或类似物，R6和R7为氢原子或C1-C6烷基，R8为苯基、任选被k个R81取代的苯基或类似物，作为活性成分的化合物的同分异构体或其药学上可接受的盐或溶液。
• CELL CULTURE METHOD, CELL AGGREGATES, CELL AGGREGATION CONTROL AGENT, AND MEDIUM
  申请人：The University of Tokyo

  公开号：EP3252154A1

  公开（公告）日：2017-12-06

  A method for culturing cells by which the diameter of cell aggregates can be controlled, and by which a large amount of cells can be obtained, a cell aggregate obtained by the method, a cell aggregation control agent, and a medium containing the cell aggregation control agent, are provided. A method for culturing cells by suspension culture, which method includes an aggregation control step of adding a substance that inhibits a cell adhesion molecule(s) of the cells to a medium to control cell aggregation of the cells, and the like are provided.

  本发明提供了一种可控制细胞聚集体直径并可获得大量细胞的细胞培养方法、通过该方法获得的细胞聚集体、细胞聚集控制剂以及含有细胞聚集控制剂的培养基。提供了一种通过悬浮培养法培养细胞的方法，该方法包括在培养基中加入抑制细胞粘附分子的物质以控制细胞聚集的聚集控制步骤等。
• Cell culture method, cell aggregates, cell aggregation control agent, and medium
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US11225644B2

  公开（公告）日：2022-01-18

  A method for culturing cells by which the diameter of cell aggregates can be controlled, and by which a large amount of cells can be obtained, a cell aggregate obtained by the method, a cell aggregation control agent, and a medium containing the cell aggregation control agent, are provided. A method for culturing cells by suspension culture, which method includes an aggregation control step of adding a substance that inhibits a cell adhesion molecule(s) of the cells to a medium to control cell aggregation of the cells, and the like are provided.

  本发明提供了一种可控制细胞聚集体直径并可获得大量细胞的细胞培养方法、通过该方法获得的细胞聚集体、细胞聚集控制剂以及含有细胞聚集控制剂的培养基。提供了一种通过悬浮培养法培养细胞的方法，该方法包括在培养基中加入抑制细胞粘附分子的物质以控制细胞聚集的聚集控制步骤等。